Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure
Background Sacubitril/valsartan improves health outcomes for heart failure with reduced ejection fraction relative to angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers, but it carries higher out‐of‐pocket costs. Neither the impact of cost nor how to integrate cost into medica...
Main Authors: | Birju R. Rao, Candace D. Speight, Larry A. Allen, Scott D. Halpern, Yi‐An Ko, Daniel D. Matlock, Miranda A. Moore, Alanna A. Morris, Laura D. Scherer, Mary C. Thomson, Peter Ubel, Neal W. Dickert |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.121.023789 |
Similar Items
-
Framing Benefits in Decision Aids: Effects of Varying Contextualizing Statements on Decisions About Sacubitril-Valsartan for Heart Failure
by: Mary C. Thomson, et al.
Published: (2021-10-01) -
Deciding Whether to Take Sacubitril/Valsartan: How Cardiologists and Patients Discuss Out‐of‐Pocket Costs
by: Birju R. Rao, et al.
Published: (2023-04-01) -
Discussing Out‐of‐Pocket Costs With Patients: Shared Decision Making for Sacubitril‐Valsartan in Heart Failure
by: Graham H. Smith, et al.
Published: (2019-01-01) -
Risk Preferences, Rationality of Choices, and Willingness to Pay for Preventive Medicine in Patients with Graves’ Thyrotoxicosis
by: Emoto N, et al.
Published: (2021-09-01) -
Sacubitril/Valsartan for heart failure
by: Wenqin Dai, MM, et al.
Published: (2022-06-01)